Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk

Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk

Abstract Approximately half of all patients with type 2 diabetes (T2D) develop a certain degree of renal impairment. In many of them, chronic kidney disease (CKD) progresses over time, eventually leading to end-stage kidney disease (ESKD) requiring dialysis and conveying a substantially increased ri...

Full description

Bibliographic Details
Main Authors: Francesco Giorgino, Jiten Vora, Peter Fenici, Anna Solini
Format: Article
Language:English
Published: BMC 2020-11-01
Series:Cardiovascular Diabetology
Subjects:
Diabetes mellitus
Renal dysfunction
Renal protection
cardiovascular risk
Online Access:http://link.springer.com/article/10.1186/s12933-020-01163-9

Internet

http://link.springer.com/article/10.1186/s12933-020-01163-9

Similar Items